Fresenius Reaffirms 2026 Outlook

By Public Technologies
  • Fresenius maintained its full-year 2026 outlook.
  • Biopharma revenue is targeted to nearly double by 2030 from 2025, with an EBIT margin of around 20%.
  • The company expects to significantly raise its longer-term Biopharma ambitions following an exclusive development agreement with WuXi Biologics.
  • The agreement provides access to up to 37 biosimilar candidates, potentially expanding the portfolio from 29 to 66 molecules over a decade.
  • Rising development spending will weigh on profitability before products contribute growth; operating cash flow will fund the agreement without additional debt.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2426078_de) on November 02, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk